Please assess the completion status of the following clinical trial:

Trial Title: Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Receipt of allogeneic hematopoietic cell transplant \>100 days prior to consent~* Documented cGVHD as defined by the NIH consensus criteria in at least one organ system other than the GI tract (for example, cGVHD of the oral cavity would qualify as a criterion)~* Endoscopic findings consistent with GI GVHD~* Must be able to swallow tablets~* Must be able to read and understand informed consent~* Adequate birth control methods for the duration of the study~Exclusion Criteria:~* \>500 mL/day of diarrhea on any 1 day within 3 days prior to the first dose of study drug~* GI infection~* Multi-organ failure or other condition that, in the opinion of the investigator, would compromise the patient's ability to complete the study.~* HIV seropositivity~* Pregnant or nursing female~* Use of any investigational drug to treat chronic GVHD within 28 days of the first dose of study drug~* Evidence of recurrent or progressing malignant disorder that was the indication for HCT

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Control
- orBec (Type: EXPERIMENTAL): Investigational drug

Based on this trial design, predict the completion outcome and termination type (if applicable).